Home
>
US Stocks
>
Zymeworks Inc
Zymeworks Inc
ZYME

Zymeworks Inc

$23.0727.86%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
23.03
Today Low/High
22.61 / 23.58
52 Week Low/High
$24.82 / $59.03
P/E ratio
-6.8088
Market Cap
$1.52B

Company Details

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks' suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks' lead clinical candidate, zanidatamab (ZW25), is a novel Azymetric™ bispecific antibody which has been granted Breakthrough Therapy designation by the FDA and is currently enrolling in a pivotal clinical trial for refractory HER2-amplified biliary tract cancer (HERIZON-BTC-01) as well as several Phase 2 clinical trials for HER2-expressing gastroesophageal and breast cancers. Zymeworks' second clinical candidate, ZW49, is a novel bispecific HER2-targeting antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks' proprietary ZymeLink™ linker and cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies.
Organisation
Zymeworks Inc
Headquaters
Vancouver, British Columbia, Canada
Employees
354
Industry
Health Technology

Discover more

Frequently Asked Questions

What is Zymeworks Inc share price today

Can Indians buy Zymeworks Inc shares?

How can I buy Zymeworks Inc shares from India?

Can Fractional shares of Zymeworks Inc be purchased?

What are the documents required to start investing in Zymeworks Inc stocks?

We are a SEBI registered investement advisor